Sarcomatrix Therapeutics will showcase its advancements in drug development for muscle diseases at the 2025 BIO CEO & Investor Conference. The company is preparing to initiate Phase 1 clinical trials for its lead candidate, S-969, in the same year. CEO David Craig is expected to highlight the significance of this progress in addressing muscle diseases, emphasizing the potential impact of their research and development efforts. The conference will serve as a platform for stakeholders to learn about Sarcomatrix’s innovative approaches and future plans in the therapeutic landscape for muscle disorders.